Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + tacrolimus
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of rituximab, a monoclonal antibody targeting CD20 on B-lymphocytes, and tacrolimus, a calcineurin inhibitor. This combination has shown superior efficacy compared to rituximab alone in treating refractory idiopathic membranous nephropathy (IMN), with higher complete and partial remission rates without significantly increasing adverse events. The typical regimen involves rituximab 1g administered intravenously once every 2 weeks (two doses total) combined with oral tacrolimus at 0.03 mg/kg/day.
02
Targets
Beyond the preview
Go deeper on rituximab + tacrolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + tacrolimus.